Abstract. Trilostane has been used to treat 6
The treatment of choice in Cushing's syndrome is surgical, directed either at the adrenal or pituitary gland depending on the aetiology in the individual patient. However, drug therapy has a role to play in lowering corticosteroid levels prior to surgery and in treating patients who are considered unfit for operation (Jeffcoate et al. 1977) . Trilostane ('Modrenal'; Sterling Research Labora¬ tories), a competitive inhibitor of the 3ß-hydroxysteroid dehydrogenase (3ß-HSD) enzyme system (Potts et al. 1978) , has been shown to have an adrenal blocking effect in the rat (Potts et al. 1978) , dog and guinea pig (Potts et al. 1975 ). Trilostane has been used successfully to treat a series of 7 patients with Cushing's syndrome (Komanicky et al. 1978) although more recently doubt has been cast on the therapeutic value of this drug (Darling & Fraser 1981) .
We describe our experience using trilostane in 6 cases of Cushing's syndrome and demonstrate that the adrenal response to the drug is variable, which may limit its usefulness as a therapeutic agent in Cushing's syndrome.
Patients and Methods

Patients
Six patients with clinical and biochemical evidence of Cushing's syndrome (Table 1) (Baker et al. 1980 ) and blood sampling was therefore performed 2 h after the first dose of the day at a time when the drug was likely to be exerting its maximum anti-adrenal effect.
Methods
Serum and urinary cortisol were measured by a fluorimetric method (Mattingly 1962) (Beastall et al. 1981) It is possible that the adrenal blocking activity is not due to trilostane itself but to a drug metabolite. Failure to respond to treatment might be due to failure to convert trilostane to an active metabolite rather than to a resistance to the effect of trilostane at the level of the adrenal gland.
In conclusion, trilostane does effectively control corticosteroid levels in some patients with Cush¬ ing's syndrome although the unpredictable nature of its action may limit its usefulness.
